Current Evidence and Therapeutic Strategies for Multiple Sclerosis

 

 Buy Article Permissions and Reprints

ABSTRACT

In the previous two decades several immunomodulatory and immunosuppressive therapies have been shown to favorably impact the inflammatory activity and course of multiple sclerosis. There are now six approved therapies for the disease. Clinical decision-making has become more complex because of the increasing number of available drugs, the lack of head-to-head comparisons that allow direct comparisons of efficacy, and special factors that may influence efficacy such as neutralizing antibodies against β-interferon preparations. Furthermore, all current therapies are partially effective; therefore, most patients experience breakthrough disease activity while using them, and there are no validated treatment failure definitions or management algorithms. This review outlines current evidence supporting efficacy of available drugs and scenarios for which more studies are required, and highlights the need for emerging therapies and strategies for multiple sclerosis management, including investigative oral and parenteral agents and combination therapy approaches.

REFERENCES

• 1 Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis.  Lancet Neurol. 2005;  4 281-288
  CrossrefPubMedGoogle Scholar
• 2 Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management.  Lancet Neurol. 2005;  4 341-348
  CrossrefPubMedGoogle Scholar
• 3 McDonald W I, Compston A, Edan G et al.. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis.  Ann Neurol. 2001;  50 121-127
  CrossrefPubMedGoogle Scholar
• 4 Polman C H, Reingold S C, Edan G et al.. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria..”  Ann Neurol. 2005;  58 840-846
  CrossrefPubMedGoogle Scholar
• 5 Brex P A, Ciccarelli O, O'Riordan J I, Sailer M, Thompson A J, Miller D H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis.  N Engl J Med. 2002;  346 158-164
  CrossrefPubMedGoogle Scholar
• 6 O'Riordan J I, Thompson A J, Kingsley D PE et al.. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up.  Brain. 1998;  121 495-503
  CrossrefPubMedGoogle Scholar
• 7 Sailer M, O'Riordan J I, Thompson A J et al.. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination.  Neurology. 1999;  52 599-606
  PubMedGoogle Scholar
• 8 CHAMPS Study Group . MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group.  Neurology. 2002;  59 998-1005
  PubMedGoogle Scholar
• 9 Jacobs L D, Beck R W, Simon J H et al.. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.  N Engl J Med. 2000;  343 898-904
  CrossrefPubMedGoogle Scholar
• 10 Comi G, Filippi M, Barkhof F et al.. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.  Lancet. 2001;  357 1576-1582
  CrossrefPubMedGoogle Scholar
• 11 Filippi M, Rovaris M, Inglese M et al.. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial.  Lancet. 2004;  364 1489-1496
  CrossrefPubMedGoogle Scholar
• 12 Kappos L, Polman C, Freedman M S et al.. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.  Neurology. 2006;  67 1242-1249
  CrossrefPubMedGoogle Scholar
• 13 CHAMPIONS Study Group . Interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.  Neurology. 2006;  66 678-684
  CrossrefPubMedGoogle Scholar
• 14 Achiron A, Kishner I, Sarova-Pinhas I et al.. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial.  Arch Neurol. 2004;  61 1515-1520
  CrossrefPubMedGoogle Scholar
• 15 The IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.  Neurology. 1993;  43 655-661
  PubMedGoogle Scholar
• 16 The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group . Interferon beta-1b in the treatment of MS: Final outcome of the randomized controlled trial.  Neurology. 1995;  45 1277-1285
  PubMedGoogle Scholar
• 17 Jacobs L D, Cookfair D L, Rudick R A et al.. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis.  Ann Neurol. 1996;  39 285-294
  CrossrefPubMedGoogle Scholar
• 18 PRISMS. (Prevention of Relapses and Disability by Interferon -1a Subcutaneously in Multiple Sclerosis) Study Group . Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis.  Lancet. 1998;  352 1498-1504
  CrossrefPubMedGoogle Scholar
• 19 PRISMS Study Group, and the University of British Columbia MS/MRI Analysis Group . PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS.  Neurology. 2001;  56 1628-1636
  PubMedGoogle Scholar
• 20 Goodin D S, Frohman E M, Garmany G P et al.. Disease modifying therapies in multiple sclerosis. Report of the Therapeutic and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.  Neurology. 2002;  58 169-178
  CrossrefPubMedGoogle Scholar
• 21 Filippini G, Munari L, Incorvaia B et al.. Interferons in relapsing remitting multiple sclerosis: a systematic review.  Lancet. 2003;  361 545-552
  CrossrefPubMedGoogle Scholar
• 22 Freedman M, King J, Oger J et al.. Interferons in relapsing remitting multiple sclerosis.  Lancet. 2003;  361 1822-1823 , Letter
  PubMedGoogle Scholar
• 23 Durelli L, Verdun E, Barbero P et al.. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).  Lancet. 2002;  359 1453-1460
  CrossrefPubMedGoogle Scholar
• 24 Panitch H, Goodin D S, Francis G et al.. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial.  Neurology. 2002;  59 1496-1506
  CrossrefPubMedGoogle Scholar
• 25 Clanet M, Radue E W, Kappos L et al.. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.  Neurology. 2002;  59 1507-1517
  CrossrefPubMedGoogle Scholar
• 26 Kappos L, Traboulsee A, Constantinescu C et al.. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.  Neurology. 2006;  67 944-953
  CrossrefPubMedGoogle Scholar
• 27 Noseworthy J H. How much can we learn from long-term extension trials in multiple sclerosis?.  Neurology. 2006;  67 930-931
  CrossrefPubMedGoogle Scholar
• 28 Sorensen P S, Koch-Henrisken N, Ravnborg M et al.. Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey.  Mult Scler. 2006;  12 253-264
  CrossrefPubMedGoogle Scholar
• 29 Ebers G, Traboulsee A, Li D et al.. Final results from the interferon beta-1b 16-year long-term follow-up study. 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis Madrid, Spain; September 2006: P666
  Google Scholar
• 30 Martinelli Boneschi F, Rovaris M, Johnson K P et al.. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.  Mult Scler. 2003;  9 349-355
  CrossrefPubMedGoogle Scholar
• 31 Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis (Cochrane Review). In: The Cochrane Library, Issue 4. Chichester, United Kingdom; John Wiley and Sons Ltd 2004
  Google Scholar
• 32 Cohen J, Rovaris M, Goodman A et al.. Randomised, double-blind, parallel-group, dose-comparison study of glatiramer acetate in relapsing-remitting multiple sclerosis. 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis Madrid, Spain; September 2006
  Google Scholar
• 33 Ford C C, Johnson K P, Lisak R P et al.. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients.  Mult Scler. 2006;  12 309-320
  CrossrefPubMedGoogle Scholar
• 34 Rice G P, Hartung H P, Calabresi P A. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.  Neurology. 2005;  64 1336-1342
  CrossrefPubMedGoogle Scholar
• 35 Miller D H, Khan O A, Sheremata W A et al.. A controlled trial of natalizumab for relapsing multiple sclerosis.  N Engl J Med. 2003;  348 15-23
  CrossrefPubMedGoogle Scholar
• 36 Van Assche G, Van Ranst M, Sciot R et al.. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease.  N Engl J Med. 2005;  353(4) 362-368
  CrossrefPubMedGoogle Scholar
• 37 Kleinschmidt-DeMasters B K, Tyler K L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.  N Engl J Med. 2005;  353(4) 369-374
  CrossrefPubMedGoogle Scholar
• 38 Langer-Gould A, Atlas S W, Green A J, Bollen A W, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab.  N Engl J Med. 2005;  353(4) 375-381
  CrossrefPubMedGoogle Scholar
• 39 Berger J R, Koralnik I J. Progressive multifocal leukoencephalopathy and natalizumab-unforeseen consequences.  N Engl J Med. 2005;  353(4) 414-416
  CrossrefPubMedGoogle Scholar
• 40 Polman C H, O'Connor P W, Havrdova E et al.. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.  N Engl J Med. 2006;  354 899-910
  CrossrefPubMedGoogle Scholar
• 41 Rudick R A, Stuart W H, Calabresi P A et al.. A randomized, placebo-controlled trial of natalizumab plus interferon beta-1a for relapsing multiple sclerosis.  N Engl J Med. 2006;  354 911-923
  CrossrefPubMedGoogle Scholar
• 42 Yousry T A, Major E O, Ryschkewitsch C et al.. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.  N Engl J Med. 2006;  354 924-933
  CrossrefPubMedGoogle Scholar
• 43 Stüve O, Marra C M, Jerome K R et al.. Immune surveillance in multiple sclerosis patients treated with natalizumab.  Ann Neurol. 2006;  59 743-747
  CrossrefPubMedGoogle Scholar
• 44 Niino M, Bodner C, Simard M L et al.. Natalizumab effects on immune cell responses in multiple sclerosis.  Ann Neurol. 2006;  59 748-754
  CrossrefPubMedGoogle Scholar
• 45 Kappos L, Bates D, Hartung H P et al.. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.  Lancet Neurol. 2007;  6 431-441
  CrossrefPubMedGoogle Scholar
• 46 Hartung H-P, Gonsette R, Konig N et al.. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, muticentre trial.  Lancet. 2002;  360 2018-2025
  CrossrefPubMedGoogle Scholar
• 47 Goodin D S, Arnason B G, Coyle P K et al.. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis.  Neurology. 2003;  61 1332-1338
  PubMedGoogle Scholar
• 48 Novantrone [package insert]. Rockland, MA; Serono Inc 2005
  Google Scholar
• 49 Ghalie R G, Edan G, Laurent M et al.. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.  Neurology. 2002;  59 909-913
  PubMedGoogle Scholar
• 50 Avasarala J R, Cross A H, Clifford D B, Singer B A, Siegel B A, Abbey E E. Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.  Mult Scler. 2003;  9(1) 59-62
  CrossrefPubMedGoogle Scholar
• 51 Edan G, Brochet B, Clanet M et al.. Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients: a 4 year mean follow-up study.  Neurology. 2004;  62(suppl 5) A493
  PubMedGoogle Scholar
• 52 Brassat D, Recher C, Waubant E et al.. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.  Neurology. 2002;  59 954-955
  PubMedGoogle Scholar
• 53 Bernitsas E, Wei W, Mikol D D. Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.  Ann Neurol. 2006;  59 206-209
  CrossrefPubMedGoogle Scholar
• 54 European Study Group on Interferon β-1b in Secondary Progressive MS . Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis.  Lancet. 1998;  352 1491-1497
  CrossrefPubMedGoogle Scholar
• 55 Cohen J A, Cutter G R, Fischer J S for the IMPACT Investigators et al. Benefit of interferon β-1a on MSFC progression in secondary progressive MS.  Neurology. 2002;  59 679-687
  CrossrefPubMedGoogle Scholar
• 56 Secondary Progressive Efficacy Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group . Randomized controlled trial of interferon-beta-1a in secondary progressive MS.  Neurology. 2001;  56 1496-1504
  PubMedGoogle Scholar
• 57 Li D K, Zhao G J, Paty D W. University of British Columbia MS/MRI Analysis Research Group, and the SPECTRIMS Study Group . Randomized controlled trial of interferon beta-1a in secondary progressive MS. MRI results.  Neurology. 2001;  56 1505-1518
  CrossrefPubMedGoogle Scholar
• 58 Panitch H, Miller A, Paty D, Weinshenker B. for the North American Study Group on Interferon beta-1b in Secondary. Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.  Neurology. 2004;  63 1788-1795
  CrossrefPubMedGoogle Scholar
• 59 Hommes O R, Sorenson P S, Fazekas F et al.. Intravenous immune globulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.  Lancet. 2004;  364 1149-1156
  CrossrefPubMedGoogle Scholar
• 60 Kappos L, Weinshenker B, Pozzilli C et al.. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.  Neurology. 2004;  63 1779-1787
  CrossrefPubMedGoogle Scholar
• 61 Cohen J A, Antel J P. Does interferon beta help in secondary progressive MS?.  Neurology. 2004;  63 1768-1769
  PubMedGoogle Scholar
• 62 Wolinsky J S, Narayana P A, O'Connor P et al.. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.  Ann Neurol. 2007;  61 14-24
  CrossrefPubMedGoogle Scholar
• 63 Freedman M S, Patry D G, Grand'Maison F, Myles M L, Paty D W, Selchen D H. Canadian MS Working Group . Treatment optimization in multiple sclerosis.  Can J Neurol Sci. 2004;  31 157-168
  CrossrefPubMedGoogle Scholar
• 64 Rudick R A, Lee J C, Simon J et al.. Defining interferon beta response status in multiple sclerosis patients.  Ann Neurol. 2004;  56 548-555
  CrossrefPubMedGoogle Scholar
• 65 Rio J, Nos V, Tintore M et al.. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.  Ann Neurol. 2006;  59 344-352
  CrossrefPubMedGoogle Scholar
• 66 Giovannoni G, Munschauer III F E, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis.  J Neurol Neurosurg Psychiatry. 2002;  73 465-469
  CrossrefPubMedGoogle Scholar
• 67 Bertolotto A, Malucchi S, Sala A et al.. Differential effects of three interferon betas on neutralizing antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.  J Neurol Neurosurg Psychiatry. 2002;  73 148-153
  CrossrefPubMedGoogle Scholar
• 68 Sorensen P S, Ross C, Clemmesen K M et al.. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.  Lancet. 2003;  362 1184-1191
  CrossrefPubMedGoogle Scholar
• 69 Bertolotto A, Gilli F, Sala A et al.. Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients.  Neurology. 2003;  60 634-639
  PubMedGoogle Scholar
• 70 Pachner A. Anti-IFNβ antibodies in IFNβ-treated MS patients: summary.  Neurology. 2003;  61(suppl 5) S1-S5
  PubMedGoogle Scholar
• 71 Sorensen P S, Koch-Henriksen N, Ross C et al.. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.  Neurology. 2005;  65 33-39
  CrossrefPubMedGoogle Scholar
• 72 Sorensen P S, Tscherning T, Mathiesen H K et al.. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.  Neurology. 2006;  67 1681-1683
  CrossrefPubMedGoogle Scholar
• 73 Francis G S, Rice G PA, Alsop J C et al.. Interferon β-1a in MS. Results following development of neutralizing antibodies in PRISMS.  Neurology. 2005;  65 48-55
  CrossrefPubMedGoogle Scholar
• 74 Kappos L, Clanet M, Sandberg-Wollheim M et al.. Neutralizing antibodies and efficacy of interferon β-1a: a 4-year controlled study.  Neurology. 2005;  65 40-47
  CrossrefPubMedGoogle Scholar
• 75 Giovannoni G, Goodman A. Neutralizing anti-IFN-β antibodies: how much more evidence do we need to use them in practice?.  Neurology. 2005;  65 6-8
  CrossrefPubMedGoogle Scholar
• 76 Sorensen P S, Deisenhammer F, Duda P EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis.  Eur J Neurol. 2005;  12 817-827
  CrossrefPubMedGoogle Scholar
• 77 Goodin D S, Frohman E M, Hurwitz B et al.. Neutralizing antibodies to interferon beta-assessment of their clinical and radiographic impact: an evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.  Neurology. 2007;  68 977-984
  CrossrefPubMedGoogle Scholar
• 78 Petersen B, Bendtzen K, Koch-Henriksen N et al.. Persistence of neutralizing antibodies after discontinuation of IFNB therapy in patients with relapsing-remitting multiple sclerosis.  Mult Scler. 2006;  12 247-252
  CrossrefPubMedGoogle Scholar
• 79 Tullman M J, Lublin F J. Combination therapy in multiple sclerosis.  Curr Neurol Neurosci Rep. 2005;  5 245-248
  CrossrefPubMedGoogle Scholar
• 80 Pulicken M, Bash C N, Costello K et al.. Optimization of the safety and efficacy of interferon beta 1b and azathioprine combination therapy in multiple sclerosis.  Mult Scler. 2005;  11 169-174
  CrossrefPubMedGoogle Scholar
• 81 Jeffery D R, Chepuri N, Durden N, Burdette J. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging.  Mult Scler. 2005;  11 296-301
  CrossrefPubMedGoogle Scholar
• 82 Smith D R, Weinstock-Guttman B, Cohen J A et al.. A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta.  Mult Scler. 2005;  11 573-582
  CrossrefPubMedGoogle Scholar
• 83 Gladstone D E, Zamkoff K W, Krupp L et al.. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.  Arch Neurol. 2006;  63 1388-1393
  CrossrefPubMedGoogle Scholar
• 84 Ramtahal J, Jacob A, Das K, Boggild M. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.  J Neurol. 2006;  253 1160-1164
  CrossrefPubMedGoogle Scholar
• 85 Cree B. Emerging monoclonal antibody therapies for multiple sclerosis.  Neurologist. 2006;  12 171-178
  CrossrefPubMedGoogle Scholar
• 86 U.S. Food and Drug Administration .Life-threatening brain infection in patients with systemic lupus erythematosus after rituxan (Rituximab) treatment. Available at: http://www.fda.gov/cder/drug/advisory/rituximab.htm Accessed May 10, 2007
  Google Scholar
• 87 Kappos L, Antel J, Comi G et al.. Oral fingolimod (FTY720) for relapsing multiple sclerosis.  N Engl J Med. 2006;  355 1124-1140
  CrossrefPubMedGoogle Scholar
• 88 O'Connor P W, Li D, Freedman M S et al.. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.  Neurology. 2006;  66 894-900
  CrossrefPubMedGoogle Scholar

Dean M WingerchukM.D. M.Sc. F.R.C.P.(C.) 

Department of Neurology, Mayo Clinic College of Medicine

13400 East Shea Boulevard, Scottsdale, AZ 85259

Email: wingerchuk.dean@mayo.edu